Consensus on diagnosis and management of non-metastatic castration resistant prostate cancer in Brazil: focus on patient, selection, treatment efficacy, side effects and physician's perception according to patient comorbidities

BACKGROUND: Non-metastatic castration resistant prostate cancer (M0 CRPC) has seen important developments in drugs and diagnostic tools in the last two years. New hormonal agents have demonstrated improvement in metastasis free survival in M0 CRPC patients and have been approved by regulatory agenci...

Descripción completa

Detalles Bibliográficos
Autores principales: Maluf, Fernando, Soares, Andrey, Avanço, Guilherme, Hada, Aline Lury, Cardoso, Ana Paula Garcia, Carneiro, Arie, Herchenhorn, Daniel, Jardim, Denis Leonardo Fontes, Schutz, Fabio Augusto, Kater, Fabio Roberto, Pereira, Felipe Moraes Toledo, Monteiro, Fernando Sabino Marques, Morbeck, Igor Alexandre Protzner, Reolon, João Francisco Navarro, da Trindade, Karine Martins, Andrade, Livia Maria Querino da Silvo, Nogueira, Lucas Mendes, Furoni, Renato, Natel, Ricardo Azze, dos Reis, Rodolfo Borges, Fogace, Rodrigo Nogueira, Souza, Vinicius Carrera
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sociedade Brasileira de Urologia 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7857750/
https://www.ncbi.nlm.nih.gov/pubmed/33284538
http://dx.doi.org/10.1590/S1677-5538.IBJU.2020.0249

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7857750/
https://www.ncbi.nlm.nih.gov/pubmed/33284538
http://dx.doi.org/10.1590/S1677-5538.IBJU.2020.0249

Ejemplares similares